RT Journal Article SR Electronic T1 OVERWHELMING GENETIC HETEROGENEITY AND EXHAUSTING MOLECULAR DIAGNOSTIC PROCESS IN CHRONIC AND PROGRESSIVE ATAXIAS: FACING IT UP WITH AN ALGORITHM, A GENE, A PANEL AT A TIME JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.03.20.20036996 DO 10.1101/2020.03.20.20036996 A1 J Perez Maturo A1 L Zavala A1 P Vega A1 D González-Morón A1 N Medina A1 V Salinas A1 J Rosales A1 M Córdoba A1 T Arakaki A1 N Garretto A1 S. Rodríguez-Quiroga A1 MA Kauffman YR 2020 UL http://medrxiv.org/content/early/2020/03/23/2020.03.20.20036996.abstract AB Ataxias is one of the most frequent complaints in Neurogenetics units worldwide. Currently, more than 50 subtypes of spinocerebellar ataxias and more than 60 recessive ataxias are recognized. We conducted an 11-year prospective, observational, analytical study in order to estimate the frequency of pediatric and adult genetic ataxias in Argentina, to describe the phenotypes of this cohort and evaluate the diagnostic yield of the algorithm used in our unit. We included 334 ataxic patients. Our diagnostic approach was successful in one third of the cohort. A final molecular diagnosis was reached in 113 subjects. This rate is significantly higher in the subgroup of patients with a positive family history, where the diagnostic yield increased to 55%. The most prevalent dominant and recessive ataxias in Argentina were SCA-2 (36% of dominant ataxias) and FA (62% of recessive ataxias), respectively. Next generation sequencing based assays were diagnostic in the 65% of the patients requiring these tests. These results provide relevant epidemiological information, bringing a comprehensive knowledge of the most prevalent subtypes of genetic ataxias and their phenotypes in our territory and laying the groundwork for rationally implementing genetic diagnostic programs for these disorders in our country.Competing Interest StatementDisclosure of potential conflicts of interest: Conflict of Interest: Josefina Perez Maturo and Valeria Salinas have received scholarship support from Argentinean National Science Council (CONICET). Marcelo Kauffman has received grant support from Ministry of Health of Buenos Aires City, Argentinean National Science Council (CONICET) and Argentinean Ministry of Science and Technology. He serves as Associate Editor of the journal Neurologia Argentina. The rest of the authors declare that they have no conflict of interest. Ethics approval: This study was approved by the Institutional Ethics Committee of the Hospital JM Ramos Mejia of Buenos Aires, Argentina. All patients and parents provided written informed consent for genetic analyses and use of their anonymized data. All experiments and methods were carried out in accordance with the relevant guidelines and regulations of the Institutional Ethics Committee of the Hospital JM Ramos Mejia of Buenos Aires, Argentina. All clinical investigations have been conducted in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Consent to participate: Informed consent for genetic analyses and use of their anonymized data, was obtained from all individual participants and/or parents included in the study. Consent to publish: Patients signed informed consent regarding publishing their dataFunding StatementFunding: This study was funded by a grant from the Ministry of Science and Technology of Argentina.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesALL DATA IS AVAILABLE AT THE MANUSCRIPT